While YM155 was well tolerated, responses in a phase I pharmacokinetic trial of YM155 in 41 patients with advanced cancers were limited, including prostate specific antigen (PSA) responses in two prostate cancer patients and one complete and two partial responses in three patients with non-Hodgkin’s lymphoma [81]. Here, KLK3 is linked to cancer.